Identification and interrogation of the gene regulatory network of CEBPA-double mutant acute myeloid leukemia.
Assunta AdamoPaulynn Suyin ChinPeter KeaneSalam A AssiSandeep PotluriSophie G KellawayDaniel ColemanLuke AmesAnetta PtasinskaH Ruud DelwelPeter N CockerillConstanze BoniferPublished in: Leukemia (2022)
Acute myeloid leukemia (AML) is a heterogeneous hematological malignancy caused by mutations in genes encoding transcriptional and epigenetic regulators together with signaling genes. It is characterized by a disturbance of differentiation and abnormal proliferation of hematopoietic progenitors. We have previously shown that each AML subtype establishes its own core gene regulatory network (GRN), consisting of transcription factors binding to their target genes and imposing a specific gene expression pattern that is required for AML maintenance. In this study, we integrate gene expression, open chromatin and ChIP data with promoter-capture Hi-C data to define a refined core GRN common to all patients with CEBPA-double mutant (CEBPA N/C ) AML. These mutations disrupt the structure of a major regulator of myelopoiesis. We identify the binding sites of mutated C/EBPα proteins in primary cells, we show that C/EBPα, AP-1 factors and RUNX1 colocalize and are required for AML maintenance, and we employ single cell experiments to link important network nodes to the specific differentiation trajectory from leukemic stem to blast cells. Taken together, our study provides an important resource which predicts the specific therapeutic vulnerabilities of this AML subtype in human cells.
Keyphrases
- acute myeloid leukemia
- gene expression
- transcription factor
- dna methylation
- allogeneic hematopoietic stem cell transplantation
- genome wide identification
- genome wide
- induced apoptosis
- bioinformatics analysis
- single cell
- high throughput
- cell cycle arrest
- dna binding
- bone marrow
- signaling pathway
- electronic health record
- squamous cell carcinoma
- big data
- dna damage
- machine learning
- early stage
- sentinel lymph node
- lymph node
- neoadjuvant chemotherapy